Microbial-origin and microbiota-mimic tumor antigens in cancer immunotherapy: from tumor-resident peptides to cross-reactive T-cell targets

Microbial peptides and microbial mimics of host antigens expand the targets and immunogens available for cancer immunotherapy. Their therapeutic roles depend on which cells present the antigen and how the resulting T-cell response reaches the tumor. Building on reviews of antigen discovery, molecular mimicry, and vaccination, this review compares the cellular mechanisms connecting recognition to tumor injury. Microbial ligands have been recovered from human tumor HLA peptidomes, and individual receptors can recognize both microbial and host peptides. Selected human cell systems connect microbial-peptide stimulation to responses against unpulsed tumor cells. Mouse experiments reveal additional routes through antigen presentation by nonmalignant host cells, local cytotoxic effects, and follicular helper T-cell-supported immune organization. Together, these findings identify different uses for microbial antigens: a ligand displayed by cancer cells can provide a direct target, a mimic can recruit tumor-reactive clones, and a locally presented microbial antigen can sustain cooperating immune populations. These routes place different demands on antigen processing, clone selection, and tissue distribution. Host antigen transfer provides a further source of immune responses, while the antigenic consequences of microbial mutagenesis remain uncharacterized. We examine how these differences affect immunogen design, receptor engineering, tumor selectivity, and interpretation of human immune monitoring. The resulting synthesis identifies testable development options without assigning a single mechanism to all microbial antigens. Human immunological findings support continued investigation; their relationship to sustained clinical benefit remains to be established.

Authors

Institutions

Publication Details

Journal
Frontiers in Immunology
Published
2026-11-13
DOI
https://doi.org/10.3389/fimmu.2026.2028689
Primary Topic
Immunotherapy and Immune Responses
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Microbial-origin and microbiota-mimic tumor antigens in cancer immunotherapy: from tumor-resident peptides to cross-reactive T-cell targets

Zilin Wang, Xin Wang, Bingsheng He
2 links
Frontiers in Immunology
Immunotherapy and Immune Responses
article

Microbial-origin and microbiota-mimic tumor antigens in cancer immunotherapy: from tumor-resident peptides to cross-reactive T-cell targets

Zilin Wang, Xin Wang, Bingsheng He
article en

Abstract

Microbial peptides and microbial mimics of host antigens expand the targets and immunogens available for cancer immunotherapy. Their therapeutic roles depend on which cells present the antigen and how the resulting T-cell response reaches the tumor. Building on reviews of antigen discovery, molecular mimicry, and vaccination, this review compares the cellular mechanisms connecting recognition to tumor injury. Microbial ligands have been recovered from human tumor HLA peptidomes, and individual receptors can recognize both microbial and host peptides. Selected human cell systems connect microbial-peptide stimulation to responses against unpulsed tumor cells. Mouse experiments reveal additional routes through antigen presentation by nonmalignant host cells, local cytotoxic effects, and follicular helper T-cell-supported immune organization. Together, these findings identify different uses for microbial antigens: a ligand displayed by cancer cells can provide a direct target, a mimic can recruit tumor-reactive clones, and a locally presented microbial antigen can sustain cooperating immune populations. These routes place different demands on antigen processing, clone selection, and tissue distribution. Host antigen transfer provides a further source of immune responses, while the antigenic consequences of microbial mutagenesis remain uncharacterized. We examine how these differences affect immunogen design, receptor engineering, tumor selectivity, and interpretation of human immune monitoring. The resulting synthesis identifies testable development options without assigning a single mechanism to all microbial antigens. Human immunological findings support continued investigation; their relationship to sustained clinical benefit remains to be established.

Frontiers in ImmunologyVol. 17
Zigong First People's Hospital (CN)
Good health and well-being
Immunotherapy and Immune Responses
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon